<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00501423</url>
  </required_header>
  <id_info>
    <org_study_id>06-034</org_study_id>
    <secondary_id>CPP SUDMED IV 051201</secondary_id>
    <nct_id>NCT00501423</nct_id>
  </id_info>
  <brief_title>Antiplatelet Drug Resistances and Ischemic Events</brief_title>
  <acronym>ADRIE</acronym>
  <official_title>Antiplatelet Drug Resistances and Ischemic Events</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pierre Fontana</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>BÃ©ziers Hospital, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Montpellier</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ministry of Health, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Swiss National Science Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Geneva</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The ADRIE study is an observational study on the clinical relevance of platelet reactivity in
      aspirin and clopidogrel treated cardiovascular patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The ADRIE study is an observational study on the clinical relevance of platelet reactivity in
      aspirin and clopidogrel treated cardiovascular patients.

      Main objective:

        -  to determine if platelet reactivity, assessed by specific and non-specific tests, is
           predictive of ischemic events during the 3-year follow-up.

      Secondary objectives:

        -  primary outcome in each pre-specified sub-group : patients with coronary artery disease,
           ischemic stroke or peripheral arterial disease as main qualifying disease at entry,

        -  to determine if platelet reactivity, assessed by specific and non-specific tests, is
           predictive of bleeding events during the 3-year follow-up,

        -  to investigate potential determinants of platelet reactivity at entry in the study
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2006</start_date>
  <completion_date type="Actual">September 2010</completion_date>
  <primary_completion_date type="Actual">September 2010</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>MACE</measure>
    <time_frame>prospective follow-up</time_frame>
    <description>adjudicating committee</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>MACE in pre-specified sub-groups</measure>
    <time_frame>prospective follow-up</time_frame>
    <description>patients with coronary artery disease, ischemic stroke or peripheral arterial disease as main qualifying disease at entry</description>
  </secondary_outcome>
  <other_outcome>
    <measure>potential determinants of platelet reactivity</measure>
    <time_frame>at inclusion</time_frame>
  </other_outcome>
  <enrollment type="Actual">771</enrollment>
  <condition>Symptomatic Atherothrombosis</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Documented symptomatic ischemic atherothrombotic disease
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Documented symptomatic ischemic atherothrombotic disease treated by aspirin,
             clopidogrel or both.

        Exclusion Criteria:

          -  Known platelet disorder

          -  Chronic treatment by antiplatelet drugs other than aspirin or clopidogrel.

          -  Chronic anticoagulant treatment

          -  Chronic non steroid anti inflammatory drug treatment

          -  Active cancer

          -  Ongoing aspirin or clopidogrel treatment taken for more than 5 years prior to
             inclusion
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pierre Fontana, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospitals Geneva, Switzerland</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jean-Luc Reny, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beziers Hospital, France</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital Geneva; Beziers and Monpellier University Hospitals, France</name>
      <address>
        <city>Geneva - Beziers - Montpellier</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 13, 2007</study_first_submitted>
  <study_first_submitted_qc>July 13, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 16, 2007</study_first_posted>
  <last_update_submitted>January 30, 2014</last_update_submitted>
  <last_update_submitted_qc>January 30, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 31, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Geneva</investigator_affiliation>
    <investigator_full_name>Pierre Fontana</investigator_full_name>
    <investigator_title>PI</investigator_title>
  </responsible_party>
  <keyword>antiplatelet drug</keyword>
  <keyword>resistance</keyword>
  <keyword>atherothrombosis</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Platelet Aggregation Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

